Research aimed at developing a new cancer immunotherapy
Project/Area Number |
18K19466
|
Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
Allocation Type | Multi-year Fund |
Review Section |
Medium-sized Section 50:Oncology and related fields
|
Research Institution | Chiba University |
Principal Investigator |
Kimura Motoko 千葉大学, 大学院医学研究院, 准教授 (00345018)
|
Project Period (FY) |
2018-06-29 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2019: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2018: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
Keywords | CD69 / がん免疫療法 / 腫瘍浸潤T細胞 / 疲弊 / 抗腫瘍効果 / CD69リガンド / Myl9/12 / CC69 / 抗体療法 |
Outline of Final Research Achievements |
This research is aimed at revealing the role of CD69 molecule on anti-tumor immune responses, and at contributing to establish a new cancer immunotherapy. CD69 has been known to regulate lymphocyte trafficking and migration, and we found that CD69 is expressed on most tumor-specific T cells infiltrated within tumor microenvironment. Importantly, our data showed that tumor growth was significantly reduced in Cd69-deficient mice as well as the mice with anti-CD69 Ab treatment, which was accompanied with enhanced anti-tumor immune responses. Our results show that CD69 is a new target for cancer immunotherapy.
|
Academic Significance and Societal Importance of the Research Achievements |
患者自身の免疫システムを活性化することにより腫瘍を攻撃する「免疫療法」は、近年目覚ましい開発が進められており、今後、さらに大きな発展が期待される。しかしその一方で、現行の免疫チェックポイント阻害剤の適応にならないがん腫や、副作用の問題、禁忌症などがあることから、新たな免疫療法の開発が常に求められている。 本研究は「CD69」というT細胞の動態システムに重要な働きをする分子に着目し、新しいがん免疫療法の確立を目指したものである。従来の免疫チェックポイント阻害薬とは、一線を画した斬新なアイディアを基にしたものであり、学術的意義、社会的意義の高い研究である。
|
Report
(3 results)
Research Products
(25 results)
-
-
-
-
-
[Journal Article] Ezh2 controls development of natural killer T cells that cause spontaneous asthma-like pathology2019
Author(s)
Tumes, D., Hirahara, K., Papadopoulos, M., Shinoda, K., Onodera, A., Kumagai, J., Ho Yip, K., Pant, H., Kokubo, K., Kiuchi, M., Aoki, A., Obata-Ninomiya, K., Tokoyoda, K., Endo, Y., Kimura, M.Y. and Nakayama, T.
-
Journal Title
J. Allergy Clin. Immunol.
Volume: -
Pages: .
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] CD69 prevents PLZFhi innate precursors from prematurely exiting the thymus and aborting NKT2 cell generation2018
Author(s)
Kimura, M.Y., Igi, A., Hayashizaki, K., Mita, Y., Shinzawa, M., Kadakia, T., Endo, Y., Ogawa, S., Yagi, R., Motohashi, S., Singer, A. and Nakayama, T.
-
Journal Title
Nat. Commun.
Volume: 9(1)
Pages: 3749
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells2018
Author(s)
Mita, Y., Kimura, M.Y., Hayashizaki, K., Koyama-Nasu, R., Ito, T., Motohashi, S., Okamoto, Y. and Nakayama, T.
-
Journal Title
Int. Immunol.
Volume: 30(12)
Pages: 559-567
DOI
Related Report
Peer Reviewed
-
-
[Presentation] CD69 Biology and Pathology2020
Author(s)
Kimura M.Y., Koyama-Nasu, R., Mita Y., Hayashizaki, K. and Nakayama T.
Organizer
11th International Symposium of IFReC, Immunology at the Forefront
Related Report
Int'l Joint Research / Invited
-
-
-
-
-
-
[Presentation] The role of CD69 on iNKT cell development in the thymus2018
Author(s)
Kimura M.Y., Igi, A., Hayashizaki K., Mita Y., Endo, Y., Ogawa, S., Singer, A. and Nakayama, T.
Organizer
KAI International Meeting 2018, Sejong University Convention Center, Seoul, Korea
Related Report
Int'l Joint Research / Invited
-
-
-
-
-
-
-
-
-
-